10 analysts have expressed a variety of opinions on Marinus Pharma MRNS over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 2 | 3 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 2 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.8, a high estimate of $28.00, and a low estimate of $2.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 20.0%.
Breaking Down Analyst Ratings: A Detailed Examination
A clear picture of Marinus Pharma's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Douglas Tsao | HC Wainwright & Co. | Lowers | Buy | $11.00 | $27.00 |
| Joon Lee | Truist Securities | Lowers | Buy | $10.00 | $25.00 |
| Brian Skorney | Baird | Lowers | Neutral | $2.00 | $20.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $27.00 | - |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $3.00 | $24.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $28.00 | - |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $27.00 | - |
| Jay Olson | Oppenheimer | Maintains | Perform | $9.00 | $9.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $24.00 | - |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $27.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Marinus Pharma. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Marinus Pharma compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Marinus Pharma's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Marinus Pharma's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Marinus Pharma analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Marinus Pharma
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Understanding the Numbers: Marinus Pharma's Finances
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Marinus Pharma showcased positive performance, achieving a revenue growth rate of 0.39% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Marinus Pharma's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -580.93%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Marinus Pharma's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -117.16%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Marinus Pharma's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -22.47%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 4.4, caution is advised due to increased financial risk.
Understanding the Relevance of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
